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Aims – Ventricular remodelling following myocardial infarction progressively leads to loss of 
contractile capacity and heart failure. Although calcineurin promotes maladaptive cardiac 
hypertrophy, we recently showed that the calcineurin splicing variant CnAβ1 has beneficial 
effects on the infarcted heart. However, whether this variant limits necrosis or improves 
remodelling is still unknown, precluding translation to the clinical arena. Here we explored 
the effects and therapeutic potential of CnA1 overexpression post-infarction. Methods and 
Results - Double transgenic mice with inducible cardiomyocyte-specific overexpression of 
CnA1 underwent left coronary artery ligation followed by reperfusion. Echocardiographic 
analysis showed depressed cardiac function in all infarcted mice 3 days post-infarction. 
Induction of CnAβ1 overexpression one week after infarction improved function and reduced 
ventricular dilatation. CnAβ1-overexpressing mice showed shorter, thicker scars and reduced 
infarct expansion, accompanied by reduced myocardial remodelling. CnAβ1 induced vascular 
endothelial growth factor (VEGF) expression in cardiomyocytes, which resulted in increased 
infarct vascularisation. This paracrine angiogenic effect of CnAβ1 was mediated by 
activation of the Akt/mTOR pathway and VEGF. Conclusions - Our results indicate that 
CnAβ1 exerts beneficial effects on the infarcted heart by promoting infarct vascularisation 
and preventing infarct expansion. These findings highlight the translational potential of 
CnAβ1 for gene-based therapies. 
Keywords: CnAβ1, calcineurin, myocardial infarction, cardiac remodelling, Akt
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Myocardial infarction remains a major cause of mortality and hospitalisation worldwide. 
Reperfusion of the blocked artery through percutaneous coronary intervention or 
thrombolytic therapy reduces infarct size and increases survival
1
. However, even if 
reperfusion therapies have allowed a dramatic reduction in immediate mortality, infarction 
survivors are at high risk of suffering from heart failure, arrhythmia and sudden death. 
Shortly after reperfusion millions of cardiomyocytes die due to oxidative stress and are 
substituted by scar tissue. The mechanical stress experienced by the ventricle progressively 
causes scar thinning and expansion, leading to dilatation of the left ventricle and other 
structural changes collectively known as remodelling
2, 3
. The surviving cardiomyocytes 
undergo hypertrophy to compensate the loss of contractile capacity, but these changes 
progressively lead to a decline in cardiac function and eventually to the development of heart 
failure. 
Far from being a passive tissue, post-infarction scar tissue is populated by different 
cell types that contribute to maintaining its integrity, regulate extracellular matrix (ECM) 
turnover and prevent dilatation
2-4
. A few days after infarction a granulation tissue is formed, 
integrated by leukocytes, new blood vessels, fibroblasts and myofibroblasts that secrete 
different ECM components, mainly collagen
5
. Inflammatory cells progressively disappear 
from the area and the scar matures into an ECM-rich fibrotic tissue
6
. The persistence of 
myofibroblasts in the infarct region contributes to tissue stability. Progressive loss of these 
cells causes thinning of the infarcted area and left ventricular dilatation. 
Whereas a strong ECM in the scar region prevents structural remodelling, collagen 
accumulation in the remote myocardium has the opposite effect. Interstitial fibrosis increases 
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passive stiffness, causes electrical remodelling and enhances arrhythmogenicity, further 
contributing to cardiac remodelling and dysfunction
2
. Therefore, ideal therapies will aim at 
promoting scar maturation while reducing interstitial fibrosis in the remote myocardium. 
The molecular mechanisms involved in post-infarction remodelling are not entirely 
understood
7
. Calcineurin generally plays a detrimental role in the heart and both protective 
and deleterious effects have been described for this protein in the response to 
ischemia/reperfusion
8-10
. It is both sufficient and necessary to induce maladaptive cardiac 
hypertrophy
11, 12
, and activation of the transcription factor NFAT by calcineurin promotes 
myocardial remodelling and chamber dilatation following infarction
13
. We recently described 
that, in contrast to other calcineurin A isoforms, the naturally-occurring splicing variant 
CnAβ1 has a beneficial effect on the heart. CnAβ1 has a unique C-terminal domain, not 
present in any other known protein, that confers it distinct properties
14
. In a chronic 
myocardial infarction model with permanent occlusion of the left coronary artery, cardiac-
specific overexpression of CnA1 has a protective effect, improving cardiac function and 
reducing long-term scar size
15
.  
The purpose of the present work was to investigate the potential benefit of CnAβ1 
overexpression in response to ischemia/reperfusion injury, to determine whether CnAβ1 is 
cardioprotective or whether its beneficial action results from post-infarction effects (i.e. 
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rtTA-CnAβ1 mice express the reverse Tet transactivator (rtTA) in a cardiomyocyte-specific 
manner
16
, which in turn induces CnAβ1 overexpression from a second transgene in a 
doxycycline-inducible fashion (Fig. 1). rtTA mice also express rtTA in a cardiomyocyte-
specific manner but lack the CnAβ1 transgene and therefore don’t overexpress CnAβ1. The 
rtTA-CnAβ1 mouse line was generated by crossing the original TetO-CnAβ1 transgenic line, 
carrying the Tet operator and the CnAβ1 cDNA (Fig. 1) with the rtTA mouse line. Both 
rtTA-CnAβ1 and rtTA mice were generated in a CBA/Black10 genetic background
16
 and 
inbred in this background for at least eight generations. Male littermates between 3-5 months 
of age were used for experiments. Doxycycline (Dox) was administered to the mice with the 
diet (0.3%) starting either 3 weeks before infarction or 1 week after infarction, and 
maintained until mice were sacrificed. 
 
Surgeries and Echocardiographic analysis 
Myocardial infarction was induced in rtTA-CnAβ1 (n=28) and rtTA mice (n=21) by ligation 
of the left coronary artery for 30 min followed by reperfusion of the artery. Surgeries were 
carried out under mechanical ventilation with 3-3.5% sevoflurane. Mice received analgesic 
treatment with buprenorphine (0.3 mg/kg s.c.) after surgery. The mortality rate in the first 24 
h post-infarction was 38%; no mortality was found afterwards. Cardiac function, chamber 
dilatation and wall thickness were analysed by transthoracic echocardiography 3 and 28 days 
after infarction, as well as in uninfarcted mice, using a Vevo 2100 system and a 45 MHz 
probe (Visualsonics, Toronto, Canada). Measurements were carried out by a blinded operator 
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with mice placed on a heating pad under light anaesthesia with sevoflurane adjusted to obtain 
a target heart rate of 500 ±50 beats per minute
15
. Two-dimensional (2D) and M-mode 
echocardiography images were recorded in long and short view at the level of the papillary 
muscles. Left ventricle (LV) end-systolic, end-diastolic volumes and LV ejection fraction 
were measured from 2D parasternal long axis using the area-length method. Animals were 
sacrificed by gradually filling the chamber with carbon dioxide.  
For the analysis of infarct size using echocardiography, regional left ventricular 
function was evaluated in the parasternal long-axis view. The left ventricle wall was 
subdivided into six segments (basal, mid and apical in the anterior and posterior walls). Each 
segment was scored by an independent blinded evaluator based of its motion and systolic 
thickening, according to the guidelines of the American Society of Echocardiography
17
 (1, 
normal or hyperkinetic; 2, hypokinetic; 3, akinetic, negligible thickening; 4, dyskinetic, 
paradoxical systolic motion; 5, aneurysmal, diastolic deformation). The number of 
dysfunctional segments was quantified and the total score representing the sum of the score 
of the six individual segments in each heart was calculated.  
All experiments were approved by the local Ethics Committee at the Centro Nacional 
de Investigaciones Cardiovasculares. The investigation conforms to the principles of 
Laboratory Animal Care which are formulated by the National Society for Medical Research 
and the Guide for the Care and Use of Laboratory Animals (US National Institutes of Health 
Publication 85-23, 1996). 
 
Western Blot 
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Western blot was carried out as previously described
18
 using the following primary 
antibodies: anti-phospho-Akt-Ser473, anti-Akt, anti-phospho-mTOR-Ser2448, anti-mTOR 
(Cell Signaling), anti-HIF1 and anti-Periostin (Novus Biochemicals), anti-VEGF, anti-Lox 
and anti-CD31 (Abcam), anti-fibronectin (Sigma). Anti-CnAβ1 has been previously 
described
14
. Brightness and contrast were linearly adjusted using Photoshop CS5. 
 
Histology and Immunohistochemistry 
Samples were fixed in paraformaldehyde (4% in PBS) for 48 h, washed in PBS, dehydrated 
and included in paraffin. Five microns-thick sections were stained following Masson’s 
trichrome protocol
14
. Images were quantified using ImageJ (NIH, USA). Scar length was 
determined in Masson’s trichrome-stained sections using the midline method, which best 
correlates with functional measurements
19
. In this method, the infarct length is measured as 
the length of the midline of the infarcted wall in which >50% of the wall thickness is 
composed of scar tissue
19
. Scar length represents the percentage of infarct length with respect 
to the length of the whole LV circumference. Medium/large blood vessels in the infarct 
region were visually scored in Masson trichrome-stained sections. These vessels would be 
>20 m in diameter and typically surrounded by a smooth muscle layer that makes them 
easily identifiable. In parallel, vessels were stained by immunohistochemistry using anti-
SMA. In both experiments, the number of vessels was determined in the infarct region only 
and divided by the infarct area. Vessels were quantified in three non-consecutive sections for 
each mouse. Capillaries were stained using biotin-conjugated Isolectin B4 (Sigma) and 
scored in two separate 40x microscope fields. Apoptosis in cardiomyocytes (in the whole 
section) and fibroblasts (in the infarct region) was analysed using Tunel and immunostaining 
with anti-troponin I (cardiomyocytes) or anti-periostin (fibroblasts). 
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RNA isolation and qRT-PCR 
After sacrificing the animals, mice were perfused with PBS, hearts were excised and samples 
from the infarct region, border zone and remote myocardium were separated and snap-frozen 
in liquid nitrogen. Total RNA was isolated using the RNeasy kit from Qiagen, with DNAse 
digestion on the column. cDNA was synthesized from 100 ng of total RNA using random 
hexamers and a High Capacity cDNA Reverse Transcription kit (Applied Biosystems) in a 10 
l reaction. Quantitative reverse-transcribed polymerase chain reaction (qRT-PCR) was 
carried out in an AB9700 thermocycler (Applied Biosystems) using Taqman chemistry or 
SYBR green (Applied Biosystems). The following Taqman probes were used: Acta1 
(Mm00808218_g1), Nppb/BNP (Mm01255770_g1), Col1a1 (Mm00801666_g1), Lox 
(Mm00495386_m1) Thy1 (Mm00493681_m1), and Acta2 (Mm01204962_gh). Gene 
expression was normalised to 18S rRNA levels quantified simultaneously using a VIC-
labelled probe (4310893E, Applied Biosystems). CnAβ1 and CD31 expression were 
quantified using SYBR green and the following primers and conditions: CnAβ1 forward: 5’-
AGAAGGTGAAGACCAGT-3’, CnAβ1 reverse: 5’-AGCAAGTTGCATAACATCATT-3’, 
CD31 forward: AATGGCAACTGGAGCGAGCACT, CD31 reverse: 
GGAGAAGGCGAGGAGGGTTAGGT; 2 min at 50° C, 10 min at 95° C and 40 cycles of 15 
sec  at 95° C, 30 sec at 60°. CnA2 primers were previously described
15
. qRT-PCR data was 
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Neonatal cardiomyocytes were isolated from rtTA-CnAβ1 and rtTA mice as described
21
. 
Neonatal mice were sacrificed by cervical dislocation. A total of 750.000 cells/well were 
seeded in 12-well plates and grown in the presence of 10% fetal calf serum (FCS) for 2 days. 
Cells were then washed and cultured in serum-free medium for 2 days in the presence of 2 
g/ml doxycycline, 0.1 mM rapamycin or DMSO (1:1000) as indicated in the figures. 
Conditioned medium was cleared by centrifugation and used for angiotube assays as follows. 
Matrigel (Becton Dickinson) diluted 1:3 in DMEM was added to 96-well plates (100 l/well) 
and allowed to polymerise for 60 min. Human umbilical cord vascular endothelial cells 
(HUVEC, Promocell)
22
 were seeded at a density of 30.000 cells/well in the presence of the 
different conditioned mediums and allowed to form tubes for 6 h. Where indicated, 
neutralising anti-VEGF antibody (R&D Systems) was added to the culture (2 ng/l). Anti-
troponin I (Abcam) was used as a negative control antibody. Pictures were taken with a 
Nikon eclipse TI microscope and the number of tube network nodes was quantified for each 




Data are presented as mean ±SE. In echocardiographic data, the same mice were analysed 3 
days and 28 days post-infarction, with non-infarcted animals representing a different group of 
mice. To test for statistical significance, data were analysed by 2-way ANOVA followed by 
Bonferroni post-test for multiple comparisons. In addition, a 2-way ANOVA with repeated 
measures followed by Bonferroni post-test was applied to compare mice at 3 days vs. 28 days 
post-infarction. Group differences in qRT-PCR and histological quantifications were 
analysed by 1-way ANOVA followed by Dunnett’s post-test to compare to Dox-untreated 
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mice. Angiotubes were analysed by student’s t-test or 2-way ANOVA followed by 
Bonferroni’s post-test depending on the number of variables. Data were analysed with 
GraphPad Prism 5.0 (Graphpad Software Inc., www.graphpad.com) and differences were 
considered statistically significant at p<0.05. 
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CnAβ1 improves cardiac function and remodelling after ischemia/reperfusion 
To determine the potential benefit of CnAβ1 overexpression in the context of myocardial 
infarction with reperfusion, we developed double transgenic mice in which CnAβ1 
expression is induced 3-4-fold specifically in cardiomyocytes upon administration of Dox in 
the diet (rtTA-CnAβ1 mice, Fig. 1). As negative controls, to test the effect of Dox itself, we 
used mice that overexpress the same rtTA transactivator but lack the CnAβ1 transgene (rtTA 
mice). As a first approach we administered Dox starting 3 weeks before surgery and 
maintained it throughout the experiment. We induced myocardial infarction by occluding the 
left coronary artery for 30 min. followed by reperfusion, and analysed the mice 3 and 28 days 
later by echocardiography. rtTA-CnAβ1 and rtTA mice showed functional decline and 
chamber dilatation 3 days post-infarction regardless of Dox treatment (Fig. 2A-D, Table 1), 
suggesting that initial infarct size and myocardial loss was analogous among all groups. At 
day 28 post-infarction we detected a significant improvement in cardiac function (left 
ventricular ejection fraction [LVEF]) in mice overexpressing CnAβ1 from 3 weeks before 
surgery (Dox Pre-MI, Fig. 2A, grey bars), while animals not receiving Dox showed no 
improvement (No Dox, Fig. 2A, white bars). Improved function was accompanied by reduced 
ventricular dilation in Dox-treated rtTA-CnAβ1 mice (Fig. 2C, Table 1). In contrast, Dox 
administration to rtTA mice had no effect on cardiac function or chamber dilation (Fig. 2B, 
2D). Of note, neither CnAβ1 nor CnA2 (the CnA splicing isoform that carries the full CnA 
autoinhibitory domain) mRNA expression showed much variation in response to myocardial 
infarction itself (Fig. 1G). 
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CnAβ1 induces recovery, rather than protection 
The results obtained at 3 days post-infarction suggested that CnAβ1 offered no protection 
against reperfusion injury whereas the improvement observed at 28 days suggested a positive 
effect post-infarction. To further discriminate between the protective and recovery effects of 
CnAβ1 overexpression, we treated rtTA-CnAβ1 mice with Dox starting one week post-
infarction, once the scar has developed (Dox post-MI, black bars). Interestingly, a significant 
enhancement of cardiac function was observed in these mice (Fig 2A), which was 
accompanied by reduced ventricular dilatation (Fig. 2C). Importantly, in all the study the 
same mice were sequentially analysed at 3 and 28 days. The functional decline observed at 3 
days post-infarction and the subsequent improvement observed at 28 days in Dox-treated 
rtTA-CnAβ1 mice (Fig. S1, Table 1), demonstrates that CnAβ1 induces functional recovery, 
rather protection from infarction. 
 
CnAβ1 prevents infarct expansion and improves remote myocardium remodelling 
We next analysed the impact that CnAβ1 overexpression has on infarct expansion. We found 
that overexpression of CnAβ1 before infarction resulted in reduced scar length 28 days post-
infarction, compared to mice untreated with Dox (Fig. 3A, Fig. S2). Importantly, a similar 
effect was achieved when CnAβ1 was induced after infarction. In Dox-treated rtTA-CnAβ1 
mice, scar length at 28 days post-infarction (20.47% ±3.85 in mice treated pre-MI; 14.23% 
±4.16 in mice treated post-MI) remained similar to that observed at 7 days in untreated mice 
(21.52% ±2.90). Echocardiographic analysis showed that CnAβ1 overexpression results in a 
reduction in the number of left ventricle segments with dysfunctional motility 28 days after 
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infarction (Table S1). This was particularly evident in the mid anterior segment, confirming 
the reduced infarct size observed by histological methods. In addition, CnAβ1-
overexpressing mice showed thicker scars than control mice (Fig. 3B), suggesting that 
CnAβ1 prevents infarct expansion. Induction of CnAβ1 also resulted in higher expression of 
collagen I1 in the scar region, together with increased expression of lysil oxydase, which 
crosslinks collagen and elastin molecules into mature fibres, the fibroblast proliferation 
marker Thy1/CD90 and -smooth muscle actin (Fig. 3C-F). We also detected increased 
expression of periostin, fibronectin and lysil oxidase proteins in the infarct region of CnAβ1 
overexpressing mice (Fig. 3G). rtTA mice showed no changes in scar length, thickness or 
expression of fibrosis markers upon Dox administration (Fig. 3A-G, Table S1). To 
investigate whether reduced infarct expansion was accompanied by improved fibroblast 
survival, we quantified the percentage of apoptotic fibroblasts by Tunel staining. As shown in 
Fig. S3A, only a very low degree of fibroblast apoptosis was detected in the infarct region 28 
days post-infarction and no significant difference among the groups was observed. 
To determine whether changes in infarct expansion were paralleled by improved 
remodelling of the remote myocardium, we analysed the cardiomyocyte area and the 
expression of heart failure markers in this region. CnAβ1 overexpression either before or 
after infarction significantly reduced the cross-sectional area of cardiomyocytes and the wall 
thickness in the remote myocardium (Fig. 4A, Table 1). This was accompanied by a 
significant reduction of -skeletal actin, BNP and collagen I1 in the remote myocardium of 
these mice (Fig. 4B-D). A trend towards reduced cardiomyocyte apoptosis was also detected 
in CnAβ1-overexpressing mice, although the percentage of apoptotic cardiomyocytes 28 days 
post-infarction was low (Fig. S3B). In contrast, Dox administration to rtTA mice had no 
effect on cardiomyocyte size or expression, heart failure or fibrosis markers or apoptosis (Fig. 
4A-D, Fig. S3B).  
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Improved vascularisation in the infarct region of CnAβ1-overexpressing mice 
The effect of CnAβ1 on infarcted hearts is reminiscent of cardiomyocyte activation of the 
hypoxia inducible factor 1 (HIF1), which drives expression of angiogenic factors and 
promotes infarct vascularisation
23
. To determine whether more active, thicker scars were 
supported by enhanced vascularisation in CnAβ1-overexpressing mice, we quantified the 
amount of blood vessels in the scar region. We observed that induction of CnAβ1 
overexpression either pre- or post-infarction increased the number of blood vessels in the 
infarcted region (Fig. 5, Fig. 6A, 6B). This was confirmed by an upregulation of CD31 and 
SMA mRNA in the same region (Fig. 6C, Fig. 3F, 3G). A mild induction in CD31 mRNA 
expression and in the number of capillaries was detected also in the remote area upon CnAβ1 
induction (Fig. 6E, 6F). 
 
CnAβ1 promotes vascularisation by activating the Akt signalling pathway 
We have previously shown that CnAβ1 activates the Akt pathway through its unique C-
terminal domain
15
. Akt is known to induce angiogenesis in the heart by promoting expression 
of VEGF
24
. We therefore investigated the role of this signalling pathway in the angiogenic 
response elicited by CnAβ1. We observed that Dox stimulation of rtTA-CnAβ1 mice induced 
expression of VEGF and the hypoxia inducible factor 1 (HIF1) in the remote myocardium 
(Fig. 7A). This was accompanied by increased CD31 expression and activation of the 
Akt/mTOR pathway. No changes were observed in rtTA mice upon Dox treatment. 
To test whether the paracrine angiogenic effect of CnAβ1 was reproduced in culture, 
we used the assay for HUVEC angiotube formation on matrigel
25
. As shown in Fig. 7B, 
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conditioned medium from Dox-treated rtTA-CnAβ1 cardiomyocytes stimulated angiotube 
formation by HUVEC, whereas that of untreated cells or rtTA cardiomyocytes had no effect. 
This effect was blocked by a neutralising anti-VEGF antibody (Fig. 7C), suggesting that 
VEGF mediates the paracrine effect of CnAβ1-overexpressing cardiomyocytes on endothelial 
cells. Interestingly, treatment of rtTA-CnAβ1 cardiomyocytes with the inhibitor of the 
Akt/mTOR pathway rapamycin blocked the induction of angiotube formation by the 
conditioned medium (Fig. 7D). Rapamycin also prevented the induction of VEGF secretion 
by Dox-treated rtTA-CnAβ1 cardiomyocytes (Fig. 7E). These results suggest that CnAβ1 
activates Akt/mTOR in cardiomyocytes to induce VEGF secretion and paracrine activation of 
angiogenesis. 
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We show here that, in contrast to other calcineurin isoforms, CnAβ1 has beneficial effects on 
the heart after reperfusion injury. CnAβ1 reduces ventricular dilatation and improves function 
even when overexpressed one week after infarction. By activating the Akt/mTOR pathway, 
CnAβ1 promotes secretion of angiogenic mediators by cardiomyocytes and enhances 
vascularisation of the infarct region, thus precluding infarct expansion and improving heart 
remodelling.  
Our results suggest that the beneficial effects of CnAβ1 overexpression involve the 
prevention of heart remodelling, rather than cardioprotection. The significant ventricular 
dilatation and decline in cardiac function observed here at day 3 post-infarction in all 
experimental groups strongly suggests that CnAβ1 exerts its beneficial effects by improving 
myocardial remodelling after infarction, rather than by protecting from reperfusion injury. 
This is further supported by the fact that induction of CnAβ1 as late as 1 week post-infarction 
improves cardiac function and reduces ventricular dilatation. The scar tissue in CnAβ1-
overexpressing mice is thicker and richer in collagen, matrix crosslinking enzymes and 
activated fibroblasts, which results in reduced infarct expansion.  
We previously showed that CnAβ1 overexpression leads to reduced scar formation 
after permanent occlusion of the left coronary artery
15
. In the chronic infarction model, scars 
from CnAβ1-overexpressing mice showed reduced fibroblast number and collagen 
expression. In contrast, Dox-treated rtTA-CnAβ1 show thicker scars with increased collagen 
expression after ischemia reperfusion. This apparent discrepancy is likely due to the different 
response to permanent ischemia and to reperfusion injury. Chronic myocardial infarction 
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eventually results in the death of most cells in the infarct region, leading to loss of 
extracellular matrix production and infarct expansion. In that context, the reduced infarct size 
observed in the presence of CnAβ1 is likely due to reduced myocardial damage, which is 
consistent with the improved function already observed 7 days post-infarction
15
. In contrast, 
reperfusion injury reduces cardiomyocyte death and promotes a stronger angiogenic response 
in the infarcted myocardium
26
. Our results suggest that CnAβ1 promotes VEGF expression 
from cardiomyocytes to improve vascularization of the infarcted region, while stimulating 
fibroblast proliferation and ECM production in this area. In addition, although we only 
detected a very low degree of fibroblast apoptosis 28 days post-infarction, we can not exclude 
the possibility that better vascularization improves fibroblast survival at earlier time points. 
The increase in fibroblasts and myofibroblasts in the scar tissue will contribute to increased 
extracellular matrix turnover and to the maintenance of the scar structure, thus preventing 
remodelling. Distinct effects on heart remodelling in response to permanent ischemia and 
reperfusion injury have been described for other factors like GDF15
27
. 
 In addition, the remote myocardium of CnAβ1-overexpressing mice shows reduced 
cardiomyocyte hypertrophy, together with lower expression of collagen and heart failure 
markers. This reduction in myocardial remodelling is likely the result of the limited infarct 
expansion. Importantly, all these effects were observed even when CnAβ1 overexpression 
was induced late after infarction, indicating that CnAβ1’s main target is not the reduction of 
cardiomyocyte death or inflammation, but the prevention of infarct expansion and chamber 
dilatation. 
Molecular therapies capable of improving ventricular function after infarction are 
scarce. Overexpression of sonic hedgehog starting 5 days post-infarction attenuates 
remodelling and improves function
28
. Inhibition of Wnt signalling with Frizzled antagonist 
peptides reduces infarct expansion and prevents ventricular dilatation
29
. This effect was also 
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achieved when the peptide was administered two weeks after infarction, suggesting that Wnt 
signalling has a detrimental effect on heart remodelling rather than on early infarct healing. In 
both cases, the improvement in cardiac remodelling was accompanied by enhanced infarct 
vascularisation. In this same regard, overexpression of the angiogenesis regulator HIF1 also 
improves vascularisation and function, and reduces infarct size in transgenic mice
23
. 
However, chronic overexpression of HIF1 has detrimental effects on the heart
30
. Similarly, 
short-term Akt activation in cardiomyocytes induces VEGF and angiogenesis but sustained 
activation induces maladaptive hypertrophy and fibrosis
24
. We show here that CnAβ1 induces 
angiogenesis by promoting VEGF expression in an Akt/mTOR-dependent manner. In 
contrast to sustained Akt activation, CnAβ1 overexpression in cardiomyocytes improves 
infarct vascularisation, cardiac remodelling and function without inducing the detrimental 
side effects observed after sustained Akt or HIF1 overexpression. 
Together our results underline the therapeutic potential of CnAβ1 and suggest that it 
may be an excellent candidate for gene therapies aimed at reducing ventricular remodelling 
and improving cardiac function post-infarction. We demonstrate that these beneficial effects 
can be achieved by inducing CnAβ1 expression late after infarction. Our work constitutes a 
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Figure 1. Cardio-specific inducible transgenic mice used in this study. A, rtTA-CnAβ1 
mice overexpress the reverse Tet transactivator (rtTA) specifically in cardiomyocytes under 
the control of the Xenopus MLC2v promoter. Upon doxycycline (Dox) administration in the 
diet, rtTA activates overexpression of CnAβ1 from a second transgene. B, Schematic 
showing the different experimental groups and Dox administration regime. C, CnAβ1 mRNA 
expression was analysed in the remote myocardium 28 days post-infarction by qRT-PCR. 
Results are expressed as mean fold induction ±SE over the values of uninjured hearts 
(indicated by a dashed line). *p<0.05 Dox-treated vs no Dox. D, rtTA mice were used as 
negative controls to test for the effect of rtTA overexpression and Dox administration 
themselves. These mice overexpress rtTA in cardiomyocytes but not CnAβ1, since they lack 
the second transgene present in rtTA-CnAβ1 mice. E, Schematic showing the rtTA mouse 
groups and Dox administration regime. F, Analysis of CnAβ1 mRNA expression in the 
remote myocardium 28 days post-infarction by qRT-PCR. Results are expressed as mean fold 
induction ±SE over the values of uninjured hearts (dashed line). n=6-15 per group. G, qRT-
PCR analysis of CnAβ1 and CnA2 mRNA expression in uninjured hearts and in the remote 
and infarct regions of the heart 28 days post-infarction. *p<0.05 compared to no infarction, 1-
way ANOVA plus Bonferroni post-test. 
 
Figure 2. Induction of CnA1 overexpression late after ischemia/reperfusion improves 
cardiac function and reduces dilatation. A Tet-on inducible transgenic mouse with 
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cardiomyocyte-specific expression of the reverse Tet transactivator (rtTA) was used. CnA1 
overexpression was induced in rtTA-CnA1 mice with doxycycline starting either 3 weeks 
before (Dox pre-MI) or 1 week after (Dox post-MI) ischemia/reperfusion (A, C). Control 
rtTA mice (B, D) lack the CnAβ1 transgene and therefore do not overexpress CnAβ1 upon 
doxycycline treatment. Ejection fraction (A, B) and left ventricular end systolic volume (C, 
D) were analysed by echocardiography 3 and 28 days post-infarction. Graphs show means 
±SE. n=6-15 per group. *p<0.05 infarcted vs no MI, ***p<0.0005 infarcted vs no MI, 
#p<0.05 Dox-treated vs no Dox, 2-way ANOVA plus Bonferroni post-test. §p<0.05 28 days 




Figure 3. CnAβ1 reduces infarct expansion. A, B Scar length (A) and thickness (B) were 
analysed 28 days post-infarction using histological methods. C-F, mRNA expression of 
collagen I1 (C), lysyl oxidase (D), Thy1 (E) and -smooth muscle actin (F) were analysed 
by qRT-PCR in the infarct region only. Results are expressed as mean fold induction ±SE 
over the values of uninjured hearts (dashed line). n=6-15 per group. *p<0.05 Dox-treated vs 
no Dox, 1-way ANOVA followed by Dunnett’s post-test. G, Western blot analysis of lysyl 
oxidase (Lox), fibronectin (Fn), periostin (Postn) and CD31 in the infarct region of rtTA-
CnAβ1 and rtTA mice 28 days post-infarction. 
 
Figure 4. Reduced myocardial remodelling in CnAβ1-overexpressing mice. A, 
Cardiomyocyte cross-sectional area was analysed 28 days post-infarction by histological 
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methods. B-D, The expression of -skeletal actin (B), BNP (C) and collagen I1 (D) mRNA 
was analysed by qRT-PCR in the remote myocardium. Results are expressed as mean fold 
induction ±SE over the values of uninjured hearts (dashed line). n=6-15 per group. *p<0.05 
Dox-treated vs no Dox, 1-way ANOVA followed by Dunnett’s post-test. 
 
Figure 5. Reduced infarct expansion in CnAβ1-overexpressing mice is accompanied by 
improved infarct vascularisation. rtTA-CnAβ1 and rtTA mice, either treated or untreated 
with doxycycline, were sacrificed 28 days post-infarction. Hearts were excised, fixed and 
stained with Masson’s trichrome protocol (left and centre) or with anti-SMA and DAPI 
(right). Histological sections of the infarct region show an increase in the number of medium 
and large vessels in CnAβ1-overexpressing mice. Vessels in Masson’s trichrome stainings 
are indicated by arrows. Bar, 100 m. 
 
Figure 6. CnAβ1 overexpression enhances infarct vascularisation. A, B, Hearts were 
isolated 28 days post-infarction and blood vessels were quantified in the infarct region by 
Masson’s trichrome staining (A) and immunohistochemistry using anti-SMA (B). C-E, 
CD31 mRNA expression was analysed in the infarct region (C), border zone (D) and remote 
area (E) by qRT-PCR. F, The number of capillaries per field was quantified in the border 
zone and remote areas of rtTA-CnAβ1 mice stimulated or not with Dox. The graph shows the 
average number of capillaries in 2 different 40x fields. For all experiments, n=6-15 per group. 
*p<0.05, **p<0.005, ***p<0.0005 Dox-treated vs no Dox, 1-way ANOVA followed by 
Dunnett’s post-test. 
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Figure 7. CnAβ1 promotes angiogenesis by inducing VEGF expression through Akt 
activation. A, Phosphorylation and/or expression of VEGF, HIF1, CD31, Akt, mTOR and 
CnAβ1 was analysed by western blot in the remote myocardium. B-E, The paracrine 
angiogenic effect of CnAβ1 was confirmed in angiotube assays. B, Neonatal cardiomyocytes 
from rtTA-CnAβ1 or rtTA mice were treated or not with doxycycline for 72 h and 
conditioned medium was used to stimulate HUVECs angiotube formation on matrigel. C, 
HUVEC angiotube formation was carried out as in (B) in the presence of a neutralising anti-
VEGF or a control antibody. D, Angiotube formation was assayed in HUVECs stimulated 
with conditioned medium from rtTA-CnAβ1 neonatal cardiomyocytes that had been treated 
with Dox and/or 2 M rapamycin or DMSO (1:10,000) as a control. B-D, *p<0.05, 
**p<0.005 +Dox vs –Dox; ##p<0.005 anti-VEGF (C) or Rapamycin (D) vs Control Ab or 
DMSO, respectively; 2-way ANOVA plus Bonferroni post-test (data in B were analysed with 
student’s t-test). n=3 independent experiments. E, VEGF in supernatants in (D) was analysed 
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 HW/BW (x1000)  5.01±0.23  5.11±0.27  4.50±0.23  5.61±0.49  5.00±0.23 
 
n   10   10   7   6   15 
Table 1. CnAβ1 reduces remodelling and improves cardiac function after myocardial 
infarction and reperfusion. Ligation of the left coronary artery (30’ ischemia followed by 
reperfusion) was performed in rtTA and rtTA-CnA1 male transgenic mice and echocardiography 
analysis was carried out 3 and 28 days later. Mean values ±SE are shown. *p<0.05 infarcted vs no 
MI, †p<0.05 Dox-treated vs no Dox, 2-way ANOVA plus Bonferroni post-test. ‡p<0.05 28 days 
post-MI vs 3 days post-MI repeated-measures 2-way ANOVA plus Bonferroni post-test. EF, 
ejection fraction; LVESV, left ventricular end systolic volume;  LVEDV, left ventricular end 
diastolic volume; LVPWd, left ventricular posterior wall in diastole; IVSd, interventricular septum 
in diastole; HW/BW, heart weight / body weight ratio; n, number of mice analysed. 
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Aims – Myocardial infarction remains a major cause of death and disability worldwide. Dead 
cardiomyocytes are substituted by a collagen scar that undergoes progressive expansion, 
leading to ventricular remodelling, loss of contractile capacity and eventually to heart failure.  
Therapies aimed directly at improving remodelling are therefore necessary. In this work we 
investigated the effect of the calcineurin splicing variant CnAβ1 on the response to 
ischemia/reperfusion and heart remodelling.  Ventricular remodelling following myocardial 
infarction progressively leads to loss of contractile capacity and heart failure. Although 
calcineurin promotes maladaptive cardiac hypertrophy, we recently showed that the 
calcineurin splicing variant CnAβ1 has beneficial effects on the infarcted heart. However, 
whether this variant limits necrosis or improves remodelling is still unknown, precluding 
translation to the clinical arena. Here we explored the effects and therapeutic potential of 
CnA1 overexpression post-infarction. Methods and Results - Double transgenic mice with 
inducible cardiomyocyte-specific overexpression of CnA1 underwent left coronary artery 
ligation followed by reperfusion. Echocardiographic analysis showed depressed cardiac 
function in all infarcted mice 3 days post-infarction. Induction of CnAβ1 overexpression one 
week after infarction improved function and reduced ventricular dilatation. CnAβ1-
overexpressing mice showed shorter, thicker scars and reduced infarct expansion, 
accompanied by reduced myocardial remodelling. CnAβ1 induced vascular endothelial 
growth factor (VEGF) expression in cardiomyocytes, which resulted in increased infarct 
vascularisation. This paracrine angiogenic effect of CnAβ1 was mediated by activation of the 
Akt/mTOR pathway and VEGF. Conclusions - Our results indicate that CnAβ1 exerts 
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beneficial effects on the infarcted heart by promoting infarct vascularisation and preventing 
infarct expansion. These findings highlight the translational potential of CnAβ1 for gene-
based therapies. 
Keywords: CnAβ1, calcineurin, myocardial infarction, cardiac remodelling, Akt
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Myocardial infarction remains a major cause of mortality and hospitalisation worldwide. 
Reperfusion of the blocked artery through percutaneous coronary intervention or 
thrombolytic therapy reduces infarct size and increases survival
1
. However, even if 
reperfusion therapies have allowed a dramatic reduction in immediate mortality, infarction 
survivors are at high risk of suffering from heart failure, arrhythmia and sudden death. 
Shortly after reperfusion millions of cardiomyocytes die due to oxidative stress and are 
substituted by scar tissue. The mechanical stress experienced by the ventricle progressively 
causes scar thinning and expansion, leading to dilatation of the left ventricle and other 
structural changes collectively known as remodelling
2, 3
. The surviving cardiomyocytes 
undergo hypertrophy to compensate the loss of contractile capacity, but these changes 
progressively lead to a decline in cardiac function and eventually to the development of heart 
failure. 
Far from being a passive tissue, post-infarction scar tissue is populated by different 
cell types that contribute to maintaining its integrity, regulate extracellular matrix (ECM) 
turnover and prevent dilatation
2-4
. A few days after infarction a granulation tissue is formed, 
integrated by leukocytes, new blood vessels, fibroblasts and myofibroblasts that secrete 
different ECM components, mainly collagen
5
. Inflammatory cells progressively disappear 
from the area and the scar matures into an ECM-rich fibrotic tissue
6
. The persistence of 
myofibroblasts in the infarct region contributes to tissue stability. Progressive loss of these 
cells causes thinning of the infarcted area and left ventricular dilatation. 
Whereas a strong ECM in the scar region prevents structural remodelling, collagen 
accumulation in the remote myocardium has the opposite effect. Interstitial fibrosis increases 
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passive stiffness, causes electrical remodelling and enhances arrhythmogenicity, further 
contributing to cardiac remodelling and dysfunction
2
. Therefore, ideal therapies will aim at 
promoting scar maturation while reducing interstitial fibrosis in the remote myocardium. 
The molecular mechanisms involved in post-infarction remodelling are not entirely 
understood
7
. Calcineurin generally plays a detrimental role in the heart and both protective 
and deleterious effects have been described for this protein in the response to 
ischemia/reperfusion
8-10
. It is both sufficient and necessary to induce maladaptive cardiac 
hypertrophy
11, 12
, and activation of the transcription factor NFAT by calcineurin promotes 
myocardial remodelling and chamber dilatation following infarction
13
. We recently described 
that, in contrast to other calcineurin A isoforms, the naturally-occurring splicing variant 
CnAβ1 has a beneficial effect on the heart. CnAβ1 has a unique C-terminal domain, not 
present in any other known protein, that confers it distinct properties
14
. In a chronic 
myocardial infarction model with permanent occlusion of the left coronary artery, cardiac-
specific overexpression of CnA1 has a protective effect, improving cardiac function and 
reducing long-term scar size
15
.  
The purpose of the present work was to investigate the potential benefit of CnAβ1 
overexpression in response to ischemia/reperfusion injury, to determine whether CnAβ1 is 
cardioprotective or whether its beneficial action results from post-infarction effects (i.e. 
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rtTA-CnAβ1 mice express the reverse Tet transactivator (rtTA) in a cardiomyocyte-specific 
manner
16
, which in turn induces CnAβ1 overexpression from a second transgene in a 
doxycycline-inducible fashion (Fig. 1). rtTA mice also express rtTA in a cardiomyocyte-
specific manner but lack the CnAβ1 transgene and therefore don’t overexpress CnAβ1. The 
rtTA-CnAβ1 mouse line was generated by crossing the original TetO-CnAβ1 transgenic line, 
carrying the Tet operator and the CnAβ1 cDNA (Fig. 1) with the rtTA mouse line. Both 
rtTA-CnAβ1 and rtTA mice were generated in a CBA/Black10 genetic background
16
 and 
inbred in this background for at least eight generations. Male littermates between 3-5 months 
of age were used for experiments. Doxycycline (Dox) was administered to the mice with the 
diet (0.3%) starting either 3 weeks before infarction or 1 week after infarction, and 
maintained until mice were sacrificed. 
 
Surgeries and Echocardiographic analysis 
Myocardial infarction was induced in rtTA-CnAβ1 (n=28) and rtTA mice (n=21) by ligation 
of the left coronary artery for 30 min followed by reperfusion of the artery. Surgeries were 
carried out under mechanical ventilation with 3-3.5% sevoflurane. Mice received analgesic 
treatment with buprenorphine (0.3 mg/kg s.c.) after surgery. The mortality rate in the first 24 
h post-infarction was 38%; no mortality was found afterwards. Cardiac function, chamber 
dilatation and wall thickness were analysed by transthoracic echocardiography 3 and 28 days 
after infarction, as well as in uninfarcted mice, using a Vevo 2100 system and a 45 MHz 
probe (Visualsonics, Toronto, Canada). Measurements were carried out by a blinded operator 
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with mice placed on a heating pad under light anaesthesia with sevoflurane adjusted to obtain 
a target heart rate of 500 ±50 beats per minute
15
. Two-dimensional (2D) and M-mode 
echocardiography images were recorded in long and short view at the level of the papillary 
muscles. Left ventricle (LV) end-systolic, end-diastolic volumes and LV ejection fraction 
were measured from 2D parasternal long axis using the area-length method. Animals were 
sacrificed by gradually filling the chamber with carbon dioxide.  
For the analysis of infarct size using echocardiography, regional left ventricular 
function was evaluated in the parasternal long-axis view. The left ventricle wall was 
subdivided into six segments (basal, mid and apical in the anterior and posterior walls). Each 
segment was scored by an independent blinded evaluator based of its motion and systolic 
thickening, according to the guidelines of the American Society of Echocardiography
17
 (1, 
normal or hyperkinetic; 2, hypokinetic; 3, akinetic, negligible thickening; 4, dyskinetic, 
paradoxical systolic motion; 5, aneurysmal, diastolic deformation). The number of 
dysfunctional segments was quantified and the total score representing the sum of the score 
of the six individual segments in each heart was calculated.  
All experiments were approved by the local Ethics Committee at the Centro Nacional 
de Investigaciones Cardiovasculares. The investigation conforms to the principles of 
Laboratory Animal Care which are formulated by the National Society for Medical Research 
and the Guide for the Care and Use of Laboratory Animals (US National Institutes of Health 
Publication 85-23, 1996). 
 
Western Blot 
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Western blot was carried out as previously described
18
 using the following primary 
antibodies: anti-phospho-Akt-Ser473, anti-Akt, anti-phospho-mTOR-Ser2448, anti-mTOR 
(Cell Signaling), anti-HIF1 and anti-Periostin (Novus Biochemicals), anti-VEGF, anti-Lox 
and anti-CD31 (Abcam), anti-fibronectin (Sigma). Anti-CnAβ1 has been previously 
described
14
. Brightness and contrast were linearly adjusted using Photoshop CS5. 
 
Histology and Immunohistochemistry 
Samples were fixed in paraformaldehyde (4% in PBS) for 48 h, washed in PBS, dehydrated 
and included in paraffin. Five microns-thick sections were stained following Masson’s 
trichrome protocol
14
. Images were quantified using ImageJ (NIH, USA). Scar length was 
determined in Masson’s trichrome-stained sections using the midline method, which best 
correlates with functional measurements
19
. In this method, the infarct length is measured as 
the length of the midline of the infarcted wall in which >50% of the wall thickness is 
composed of scar tissue
19
. Scar length represents the percentage of infarct length with respect 
to the length of the whole LV circumference. Medium/large blood vessels in the infarct 
region were visually scored in Masson trichrome-stained sections. These vessels would be 
>20 m in diameter and typically surrounded by a smooth muscle layer that makes them 
easily identifiable. In parallel, vessels were stained by immunohistochemistry using anti-
SMA. In both experiments, the number of vessels was determined in the infarct region only 
and divided by the infarct area. Vessels were quantified in three non-consecutive sections for 
each mouse. Capillaries were stained using biotin-conjugated Isolectin B4 (Sigma) and 
scored in two separate 40x microscope fields. Apoptosis in cardiomyocytes (in the whole 
section) and fibroblasts (in the infarct region) was analysed using Tunel and immunostaining 
with anti-troponin I (cardiomyocytes) or anti-periostin (fibroblasts). 
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RNA isolation and qRT-PCR 
After sacrificing the animals, mice were perfused with PBS, hearts were excised and samples 
from the infarct region, border zone and remote myocardium were separated and snap-frozen 
in liquid nitrogen. Total RNA was isolated using the RNeasy kit from Qiagen, with DNAse 
digestion on the column. cDNA was synthesized from 100 ng of total RNA using random 
hexamers and a High Capacity cDNA Reverse Transcription kit (Applied Biosystems) in a 10 
l reaction. Quantitative reverse-transcribed polymerase chain reaction (qRT-PCR) was 
carried out in an AB9700 thermocycler (Applied Biosystems) using Taqman chemistry or 
SYBR green (Applied Biosystems). The following Taqman probes were used: Acta1 
(Mm00808218_g1), Nppb/BNP (Mm01255770_g1), Col1a1 (Mm00801666_g1), Lox 
(Mm00495386_m1) Thy1 (Mm00493681_m1), and Acta2 (Mm01204962_gh). Gene 
expression was normalised to 18S rRNA levels quantified simultaneously using a VIC-
labelled probe (4310893E, Applied Biosystems). CnAβ1 and CD31 expression were 
quantified using SYBR green and the following primers and conditions: CnAβ1 forward: 5’-
AGAAGGTGAAGACCAGT-3’, CnAβ1 reverse: 5’-AGCAAGTTGCATAACATCATT-3’, 
CD31 forward: AATGGCAACTGGAGCGAGCACT, CD31 reverse: 
GGAGAAGGCGAGGAGGGTTAGGT; 2 min at 50° C, 10 min at 95° C and 40 cycles of 15 
sec  at 95° C, 30 sec at 60°. CnA2 primers were previously described
15
. qRT-PCR data was 
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Neonatal cardiomyocytes were isolated from rtTA-CnAβ1 and rtTA mice as described
21
. 
Neonatal mice were sacrificed by cervical dislocation. A total of 750.000 cells/well were 
seeded in 12-well plates and grown in the presence of 10% fetal calf serum (FCS) for 2 days. 
Cells were then washed and cultured in serum-free medium for 2 days in the presence of 2 
g/ml doxycycline, 0.1 mM rapamycin or DMSO (1:1000) as indicated in the figures. 
Conditioned medium was cleared by centrifugation and used for angiotube assays as follows. 
Matrigel (Becton Dickinson) diluted 1:3 in DMEM was added to 96-well plates (100 l/well) 
and allowed to polymerise for 60 min. Human umbilical cord vascular endothelial cells 
(HUVEC, Promocell)
22
 were seeded at a density of 30.000 cells/well in the presence of the 
different conditioned mediums and allowed to form tubes for 6 h. Where indicated, 
neutralising anti-VEGF antibody (R&D Systems) was added to the culture (2 ng/l). Anti-
troponin I (Abcam) was used as a negative control antibody. Pictures were taken with a 
Nikon eclipse TI microscope and the number of tube network nodes was quantified for each 




Data are presented as mean ±SE. In echocardiographic data, the same mice were analysed 3 
days and 28 days post-infarction, with non-infarcted animals representing a different group of 
mice. To test for statistical significance, data were analysed by 2-way ANOVA followed by 
Bonferroni post-test for multiple comparisons. In addition, a 2-way ANOVA with repeated 
measures followed by Bonferroni post-test was applied to compare mice at 3 days vs. 28 days 
post-infarction. Group differences in qRT-PCR and histological quantifications were 
analysed by 1-way ANOVA followed by Dunnett’s post-test to compare to Dox-untreated 
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mice. Angiotubes were analysed by student’s t-test or 2-way ANOVA followed by 
Bonferroni’s post-test depending on the number of variables. Data were analysed with 
GraphPad Prism 5.0 (Graphpad Software Inc., www.graphpad.com) and differences were 
considered statistically significant at p<0.05. 
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CnAβ1 improves cardiac function and remodelling after ischemia/reperfusion 
To determine the potential benefit of CnAβ1 overexpression in the context of myocardial 
infarction with reperfusion, we developed double transgenic mice in which CnAβ1 
expression is induced 3-4-fold specifically in cardiomyocytes upon administration of Dox in 
the diet (rtTA-CnAβ1 mice, Fig. S1). As negative controls, to test the effect of Dox itself, we 
used mice that overexpress the same rtTA transactivator but lack the CnAβ1 transgene (rtTA 
mice). As a first approach we administered Dox starting 3 weeks before surgery and 
maintained it throughout the experiment. We induced myocardial infarction by occluding the 
left coronary artery for 30 min. followed by reperfusion, and analysed the mice 3 and 28 days 
later by echocardiography. rtTA-CnAβ1 and rtTA mice showed functional decline and 
chamber dilatation 3 days post-infarction regardless of Dox treatment (Fig. 1A2A-D, Table 
1), suggesting that initial infarct size and myocardial loss was analogous among all groups. 
At day 28 post-infarction we detected a significant improvement in cardiac function (left 
ventricular ejection fraction [LVEF]) in mice overexpressing CnAβ1 from 3 weeks before 
surgery (Dox Pre-MI, Fig. 1A2A, grey bars), while animals not receiving Dox showed no 
improvement (No Dox, Fig. 1A2A, white bars). Improved function was accompanied by 
reduced ventricular dilation in Dox-treated rtTA-CnAβ1 mice (Fig. 1C2C, Table 1). In 
contrast, Dox administration to rtTA mice had no effect on cardiac function or chamber 
dilation (Fig. 2B, 2D). Of note, neither CnAβ1 nor CnA2 (the CnA splicing isoform that 
carries the full CnA autoinhibitory domain) mRNA expression showed much variation in 
response to myocardial infarction itself (Fig. S1G). 
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CnAβ1 induces recovery, rather than protection 
The results obtained at 3 days post-infarction suggested that CnAβ1 offered no protection 
against reperfusion injury whereas the improvement observed at 28 days suggested a positive 
effect post-infarction. To further discriminate between the protective and recovery effects of 
CnAβ1 overexpression, we treated rtTA-CnAβ1 mice with Dox starting one week post-
infarction, once the scar has developed (Dox post-MI, black bars). Interestingly, a significant 
enhancement of cardiac function was observed in these mice (Fig 1A2A), which was 
accompanied by reduced ventricular dilatation (Fig. 1C2C). Importantly, in all the study the 
same mice were sequentially analysed at 3 and 28 days. The functional decline observed at 3 
days post-infarction and the subsequent improvement observed at 28 days in Dox-treated 
rtTA-CnAβ1 mice (Fig. 2S1, Table 1), demonstrates that CnAβ1 induces functional recovery, 
rather protection from infarction. 
 
CnAβ1 prevents infarct expansion and improves remote myocardium remodelling 
We next analysed the impact that CnAβ1 overexpression has on infarct expansion. We found 
that overexpression of CnAβ1 before infarction resulted in reduced scar length 28 days post-
infarction, compared to mice untreated with Dox (Fig. 3A, Fig. S2). Importantly, a similar 
effect was achieved when CnAβ1 was induced after infarction. In Dox-treated rtTA-CnAβ1 
mice, scar length at 28 days post-infarction (20.47% ±3.85 in mice treated pre-MI; 14.23% 
±4.16 in mice treated post-MI) remained similar to that observed at 7 days in untreated mice 
(21.52% ±2.90). Echocardiographic analysis showed that CnAβ1 overexpression results in a 
reduction in the number of left ventricle segments with dysfunctional motility 28 days after 
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infarction (Table S1). This was particularly evident in the mid anterior segment, confirming 
the reduced infarct size observed by histological methods. In addition, CnAβ1-
overexpressing mice showed thicker scars than control mice (Fig. 3B), suggesting that 
CnAβ1 prevents infarct expansion. Induction of CnAβ1 also resulted in higher expression of 
collagen I1 in the scar region, together with increased expression of lysil oxydase, which 
crosslinks collagen and elastin molecules into mature fibres, the fibroblast proliferation 
marker Thy1/CD90 and -smooth muscle actin (Fig. 3C-F). We also detected increased 
expression of periostin, fibronectin and lysil oxidase proteins in the infarct region of CnAβ1 
overexpressing mice (Fig. 3G). rtTA mice showed no changes in scar length, thickness or 
expression of fibrosis markers upon Dox administration (Fig. 3A-G, Table S1). To 
investigate whether reduced infarct expansion was accompanied by improved fibroblast 
survival, we quantified the percentage of apoptotic fibroblasts by Tunel staining. As shown in 
Fig. S4AS3A, only a very low degree of fibroblast apoptosis was detected in the infarct 
region 28 days post-infarction and no significant difference among the groups was observed. 
To determine whether changes in infarct expansion were paralleled by improved 
remodelling of the remote myocardium, we analysed the cardiomyocyte area and the 
expression of heart failure markers in this region. CnAβ1 overexpression either before or 
after infarction significantly reduced the cross-sectional area of cardiomyocytes and the wall 
thickness in the remote myocardium (Fig. 4A, Table 1). This was accompanied by a 
significant reduction of -skeletal actin, BNP and collagen I1 in the remote myocardium of 
these mice (Fig. 4B-D). A trend towards reduced cardiomyocyte apoptosis was also detected 
in CnAβ1-overexpressing mice, although the percentage of apoptotic cardiomyocytes 28 days 
post-infarction was low (Fig. S4BS3B). In contrast, Dox administration to rtTA mice had no 
effect on cardiomyocyte size or expression, heart failure or fibrosis markers or apoptosis (Fig. 
4A-D, Fig. S4BS3B).  
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Improved vascularisation in the infarct region of CnAβ1-overexpressing mice 
The effect of CnAβ1 on infarcted hearts is reminiscent of cardiomyocyte activation of the 
hypoxia inducible factor 1 (HIF1), which drives expression of angiogenic factors and 
promotes infarct vascularisation
23
. To determine whether more active, thicker scars were 
supported by enhanced vascularisation in CnAβ1-overexpressing mice, we quantified the 
amount of blood vessels in the scar region. We observed that induction of CnAβ1 
overexpression either pre- or post-infarction increased the number of blood vessels in the 
infarcted region (Fig. S35, Fig. 5A6A, 5B6B). This was confirmed by an upregulation of 
CD31 and SMA mRNA in the same region (Fig. 5B6C, Fig. 3F, 3G). A mild induction in 
CD31 mRNA expression and in the number of capillaries was detected also in the remote 
area upon CnAβ1 induction (Fig. 5E6E, 5F6F). 
 
CnAβ1 promotes vascularisation by activating the Akt signalling pathway 
We have previously shown that CnAβ1 activates the Akt pathway through its unique C-
terminal domain
15
. Akt is known to induce angiogenesis in the heart by promoting expression 
of VEGF
24
. We therefore investigated the role of this signalling pathway in the angiogenic 
response elicited by CnAβ1. We observed that Dox stimulation of rtTA-CnAβ1 mice induced 
expression of VEGF and the hypoxia inducible factor 1 (HIF1) in the remote myocardium 
(Fig. 6A7A). This was accompanied by increased CD31 expression and activation of the 
Akt/mTOR pathway. No changes were observed in rtTA mice upon Dox treatment. 
To test whether the paracrine angiogenic effect of CnAβ1 was reproduced in culture, 
we used the assay for HUVEC angiotube formation on matrigel
25
. As shown in Fig. 6B7B, 
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conditioned medium from Dox-treated rtTA-CnAβ1 cardiomyocytes stimulated angiotube 
formation by HUVEC, whereas that of untreated cells or rtTA cardiomyocytes had no effect. 
This effect was blocked by a neutralising anti-VEGF antibody (Fig. 6C7C), suggesting that 
VEGF mediates the paracrine effect of CnAβ1-overexpressing cardiomyocytes on endothelial 
cells. Interestingly, treatment of rtTA-CnAβ1 cardiomyocytes with the inhibitor of the 
Akt/mTOR pathway rapamycin blocked the induction of angiotube formation by the 
conditioned medium (Fig. 6D7D). Rapamycin also prevented the induction of VEGF 
secretion by Dox-treated rtTA-CnAβ1 cardiomyocytes (Fig. 6E7E). These results suggest 
that CnAβ1 activates Akt/mTOR in cardiomyocytes to induce VEGF secretion and paracrine 
activation of angiogenesis. 
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We show here that, in contrast to other calcineurin isoforms, CnAβ1 has beneficial effects on 
the heart after reperfusion injury. CnAβ1 reduces ventricular dilatation and improves function 
even when overexpressed one week after infarction. By activating the Akt/mTOR pathway, 
CnAβ1 promotes secretion of angiogenic mediators by cardiomyocytes and enhances 
vascularisation of the infarct region, thus precluding infarct expansion and improving heart 
remodelling.  
Our results suggest that the beneficial effects of CnAβ1 overexpression involve the 
prevention of heart remodelling, rather than cardioprotection. The significant ventricular 
dilatation and decline in cardiac function observed here at day 3 post-infarction in all 
experimental groups strongly suggests that CnAβ1 exerts its beneficial effects by improving 
myocardial remodelling after infarction, rather than by protecting from reperfusion injury. 
This is further supported by the fact that induction of CnAβ1 as late as 1 week post-infarction 
improves cardiac function and reduces ventricular dilatation. The scar tissue in CnAβ1-
overexpressing mice is thicker and richer in collagen, matrix crosslinking enzymes and 
activated fibroblasts, which results in reduced infarct expansion.  
We previously showed that CnAβ1 overexpression leads to reduced scar formation 
after permanent occlusion of the left coronary artery
15
. In the chronic infarction model, scars 
from CnAβ1-overexpressing mice showed reduced fibroblast number and collagen 
expression. In contrast, Dox-treated rtTA-CnAβ1 show thicker scars with increased collagen 
expression after ischemia reperfusion. This apparent discrepancy is likely due to the different 
response to permanent ischemia and to reperfusion injury. Chronic myocardial infarction 
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eventually results in the death of most cells in the infarct region, leading to loss of 
extracellular matrix production and infarct expansion. In that context, the reduced infarct size 
observed in the presence of CnAβ1 is likely due to reduced myocardial damage, which is 
consistent with the improved function already observed 7 days post-infarction
15
. In contrast, 
reperfusion injury reduces cardiomyocyte death and promotes a stronger angiogenic response 
in the infarcted myocardium
26
. Our results suggest that CnAβ1 promotes VEGF expression 
from cardiomyocytes to improve vascularization of the infarcted region, while stimulating 
fibroblast proliferation and ECM production in this area. In addition, although we only 
detected a very low degree of fibroblast apoptosis 28 days post-infarction, we can not exclude 
the possibility that better vascularization improves fibroblast survival at earlier time points. 
The increase in fibroblasts and myofibroblasts in the scar tissue will contribute to increased 
extracellular matrix turnover and to the maintenance of the scar structure, thus preventing 
remodelling. Distinct effects on heart remodelling in response to permanent ischemia and 
reperfusion injury have been described for other factors like GDF15
27
. 
 In addition, the remote myocardium of CnAβ1-overexpressing mice shows reduced 
cardiomyocyte hypertrophy, together with lower expression of collagen and heart failure 
markers. This reduction in myocardial remodelling is likely the result of the limited infarct 
expansion. Importantly, all these effects were observed even when CnAβ1 overexpression 
was induced late after infarction, indicating that CnAβ1’s main target is not the reduction of 
cardiomyocyte death or inflammation, but the prevention of infarct expansion and chamber 
dilatation. 
Molecular therapies capable of improving ventricular function after infarction are 
scarce. Overexpression of sonic hedgehog starting 5 days post-infarction attenuates 
remodelling and improves function
28
. Inhibition of Wnt signalling with Frizzled antagonist 
peptides reduces infarct expansion and prevents ventricular dilatation
29
. This effect was also 
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achieved when the peptide was administered two weeks after infarction, suggesting that Wnt 
signalling has a detrimental effect on heart remodelling rather than on early infarct healing. In 
both cases, the improvement in cardiac remodelling was accompanied by enhanced infarct 
vascularisation. In this same regard, overexpression of the angiogenesis regulator HIF1 also 
improves vascularisation and function, and reduces infarct size in transgenic mice
23
. 
However, chronic overexpression of HIF1 has detrimental effects on the heart
30
. Similarly, 
short-term Akt activation in cardiomyocytes induces VEGF and angiogenesis but sustained 
activation induces maladaptive hypertrophy and fibrosis
24
. We show here that CnAβ1 induces 
angiogenesis by promoting VEGF expression in an Akt/mTOR-dependent manner. In 
contrast to sustained Akt activation, CnAβ1 overexpression in cardiomyocytes improves 
infarct vascularisation, cardiac remodelling and function without inducing the detrimental 
side effects observed after sustained Akt or HIF1 overexpression. 
Together our results underline the therapeutic potential of CnAβ1 and suggest that it 
may be an excellent candidate for gene therapies aimed at reducing ventricular remodelling 
and improving cardiac function post-infarction. We demonstrate that these beneficial effects 
can be achieved by inducing CnAβ1 expression late after infarction. Our work constitutes a 
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Figure 1. Cardio-specific inducible transgenic mice used in this study. A, rtTA-CnAβ1 
mice overexpress the reverse Tet transactivator (rtTA) specifically in cardiomyocytes under 
the control of the Xenopus MLC2v promoter. Upon doxycycline (Dox) administration in the 
diet, rtTA activates overexpression of CnAβ1 from a second transgene. B, Schematic 
showing the different experimental groups and Dox administration regime. C, CnAβ1 mRNA 
expression was analysed in the remote myocardium 28 days post-infarction by qRT-PCR. 
Results are expressed as mean fold induction ±SE over the values of uninjured hearts 
(indicated by a dashed line). *p<0.05 Dox-treated vs no Dox. D, rtTA mice were used as 
negative controls to test for the effect of rtTA overexpression and Dox administration 
themselves. These mice overexpress rtTA in cardiomyocytes but not CnAβ1, since they lack 
the second transgene present in rtTA-CnAβ1 mice. E, Schematic showing the rtTA mouse 
groups and Dox administration regime. F, Analysis of CnAβ1 mRNA expression in the 
remote myocardium 28 days post-infarction by qRT-PCR. Results are expressed as mean fold 
induction ±SE over the values of uninjured hearts (dashed line). n=6-15 per group. G, qRT-
PCR analysis of CnAβ1 and CnA2 mRNA expression in uninjured hearts and in the remote 
and infarct regions of the heart 28 days post-infarction. *p<0.05 compared to no infarction, 1-
way ANOVA plus Bonferroni post-test. 
 
Figure 12. Induction of CnA1 overexpression late after ischemia/reperfusion improves 
cardiac function and reduces dilatation. A Tet-on inducible transgenic mouse with 
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cardiomyocyte-specific expression of the reverse Tet transactivator (rtTA) was used. CnA1 
overexpression was induced in rtTA-CnA1 mice with doxycycline starting either 3 weeks 
before (Dox pre-MI) or 1 week after (Dox post-MI) ischemia/reperfusion (A, C). Control 
rtTA mice (B, D) lack the CnAβ1 transgene and therefore do not overexpress CnAβ1 upon 
doxycycline treatment. Ejection fraction (A, B) and left ventricular end systolic volume (C, 
D) were analysed by echocardiography 3 and 28 days post-infarction. Graphs show means 
±SE. n=6-15 per group. *p<0.05 infarcted vs no MI, ***p<0.0005 infarcted vs no MI, 
#p<0.05 Dox-treated vs no Dox, 2-way ANOVA plus Bonferroni post-test. §p<0.05 28 days 
post-MI vs 3 days post-MI repeated-measures 2-way ANOVA followed by Bonferroni post-
test. 
 
Figure 2. Echocardiographic analysis shows post-infarction functional improvement 
after CnAβ1 overexpression in the same animal. CnA1 overexpression was induced in 
rtTA-CnA1 mice with doxycycline starting either 3 weeks before (Dox pre-MI) or 1 week 
after (Dox post-MI) ischemia/reperfusion. rtTA mice either treated or untreated with 
doxycycline were used as negative controls. M-Mode echocardiographic analysis in the long 
axis was carried out 3 and 28 days post-infarction. Images are shown for one mouse per 
group, the same mouse at both time points. Note that mice from all groups show poor 
contraction of the anterior wall at 3 days. 
 
Figure 3. CnAβ1 reduces infarct expansion. A, B Scar length (A) and thickness (B) were 
analysed 28 days post-infarction using histological methods. C-F, mRNA expression of 
collagen I1 (C), lysyl oxidase (D), Thy1 (E) and -smooth muscle actin (F) were analysed 
by qRT-PCR in the infarct region only. Results are expressed as mean fold induction ±SE 
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over the values of uninjured hearts (dashed line). n=6-15 per group. *p<0.05 Dox-treated vs 
no Dox, 1-way ANOVA followed by Dunnett’s post-test. G, Western blot analysis of lysyl 
oxidase (Lox), fibronectin (Fn), periostin (Postn) and CD31 in the infarct region of rtTA-
CnAβ1 and rtTA mice 28 days post-infarction. 
 
Figure 4. Reduced myocardial remodelling in CnAβ1-overexpressing mice. A, 
Cardiomyocyte cross-sectional area was analysed 28 days post-infarction by histological 
methods. B-D, The expression of -skeletal actin (B), BNP (C) and collagen I1 (D) mRNA 
was analysed by qRT-PCR in the remote myocardium. Results are expressed as mean fold 
induction ±SE over the values of uninjured hearts (dashed line). n=6-15 per group. *p<0.05 
Dox-treated vs no Dox, 1-way ANOVA followed by Dunnett’s post-test. 
 
Figure 5. Reduced infarct expansion in CnAβ1-overexpressing mice is accompanied by 
improved infarct vascularisation. rtTA-CnAβ1 and rtTA mice, either treated or untreated 
with doxycycline, were sacrificed 28 days post-infarction. Hearts were excised, fixed and 
stained with Masson’s trichrome protocol (left and centre) or with anti-SMA and DAPI 
(right). Histological sections of the infarct region show an increase in the number of medium 
and large vessels in CnAβ1-overexpressing mice. Vessels in Masson’s trichrome stainings 
are indicated by arrows. Bar, 100 m. 
 
Figure 56. CnAβ1 overexpression enhances infarct vascularisation. A, B, Hearts were 
isolated 28 days post-infarction and blood vessels were quantified in the infarct region by 
Masson’s trichrome staining (A) and immunohistochemistry using anti-SMA (B). C-E, 
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CD31 mRNA expression was analysed in the infarct region (C), border zone (D) and remote 
area (E) by qRT-PCR. F, The number of capillaries per field was quantified in the border 
zone and remote areas of rtTA-CnAβ1 mice stimulated or not with Dox. The graph shows the 
average number of capillaries in 2 different 40x fields. For all experiments, n=6-15 per group. 
*p<0.05, **p<0.005, ***p<0.0005 Dox-treated vs no Dox, 1-way ANOVA followed by 
Dunnett’s post-test. 
 
Figure 67. CnAβ1 promotes angiogenesis by inducing VEGF expression through Akt 
activation. A, Phosphorylation and/or expression of VEGF, HIF1, CD31, Akt, mTOR and 
CnAβ1 was analysed by western blot in the remote myocardium. B-E, The paracrine 
angiogenic effect of CnAβ1 was confirmed in angiotube assays. B, Neonatal cardiomyocytes 
from rtTA-CnAβ1 or rtTA mice were treated or not with doxycycline for 72 h and 
conditioned medium was used to stimulate HUVECs angiotube formation on matrigel. C, 
HUVEC angiotube formation was carried out as in (B) in the presence of a neutralising anti-
VEGF or a control antibody. D, Angiotube formation was assayed in HUVECs stimulated 
with conditioned medium from rtTA-CnAβ1 neonatal cardiomyocytes that had been treated 
with Dox and/or 2 M rapamycin or DMSO (1:10,000) as a control. B-D, *p<0.05, 
**p<0.005 +Dox vs –Dox; ##p<0.005 anti-VEGF (C) or Rapamycin (D) vs Control Ab or 
DMSO, respectively; 2-way ANOVA plus Bonferroni post-test (data in B were analysed with 
student’s t-test). n=3 independent experiments. E, VEGF in supernatants in (D) was analysed 
by western blot. 
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 HW/BW (x1000)  5.01±0.23  5.11±0.27  4.50±0.23  5.61±0.49  5.00±0.23 
 
n   10   10   7   6   15 
Table 1. CnAβ1 reduces remodelling and improves cardiac function after myocardial 
infarction and reperfusion. Ligation of the left coronary artery (30’ ischemia followed by 
reperfusion) was performed in rtTA and rtTA-CnA1 male transgenic mice and echocardiography 
analysis was carried out 3 and 28 days later. Mean values ±SE are shown. *p<0.05 infarcted vs no 
MI, †p<0.05 Dox-treated vs no Dox, 2-way ANOVA plus Bonferroni post-test. ‡p<0.05 28 days 
post-MI vs 3 days post-MI repeated-measures 2-way ANOVA plus Bonferroni post-test. EF, 
ejection fraction; LVESV, left ventricular end systolic volume;  LVEDV, left ventricular end 
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diastolic volume; LVPWd, left ventricular posterior wall in diastole; IVSd, interventricular septum 
in diastole; HW/BW, heart weight / body weight ratio; n, number of mice analysed. 
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 Total score  12.8±1.03  8.7±0.91*  8.7±1.32*  11.2±1.80  11.0±1.09 
 
n   10   10   7   6   15 
 
Table S1. CnAβ1 improves cardiac motility and reduces infarct size after myocardial 
infarction and reperfusion. Ligation of the left coronary artery (30’ ischemia followed by 
reperfusion) was performed in rtTA and rtTA-CnA1 transgenic mice and echocardiography 
analysis was carried out 28 days later in the long axis. Regional left ventricular function was 
evaluated by echocardiography in the parasternal long-axis view and scored as follows: 1, normal 
or hyperkinesis; 2, hypokinesis; 3, akinesis (negligible thickening); 4, dyskinesis (paradoxical 
systolic motion); 5, aneurysmal (diastolic deformation). Mean values ±SE are shown for each of 
the six LV segments. n Dysfunctional segments represents the number of segments with abnormal 
function. Total score represents the sum of the score of the six segments. *p<0.05 Dox-treated vs 
no Dox (student’s t-test for rtTA mice and 1-way ANOVA followed by Bonferroni post-test for 
rtTA-CnAβ1 mice). 
 
Supplementary Text and Table S1
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Figure S1. Echocardiographic analysis shows post-infarction functional improvement 
after CnAβ1 overexpression in the same animal. CnA1 overexpression was induced in 
rtTA-CnA1 mice with doxycycline starting either 3 weeks before (Dox pre-MI) or 1 week 
after (Dox post-MI) ischemia/reperfusion. rtTA mice either treated or untreated with 
doxycycline were used as negative controls. M-Mode echocardiographic analysis in the long 
axis was carried out 3 and 28 days post-infarction. Images are shown for one mouse per 
group, the same mouse at both time points. Note that mice from all groups show poor 
contraction of the anterior wall at 3 days. 
 
Figure S2. CnAβ1-overexpressing mice show shorter and thicker infarcts. This figure 
illustrates quantifications in Fig. 3. rtTA-CnAβ1 and rtTA mice, either treated or untreated 
with doxycycline, were sacrificed 28 days post-infarction. Hearts were excised, fixed and 
stained with Masson’s trichrome protocol. Left ventricular sections show thicker and shorter 
scars in CnAβ1-overexpressing mice. Two images are shown per condition. Bar, 1 mm. 
 
Figure S3. CnAβ1 overexpression results in a mild reduction in apoptotic 
cardiomyocytes 28 days post-infarction. A, B, Hearts from rtTA-CnAβ1 and rtTA mice 
were analysed by immunohistochemistry using Tunel staining. Fibroblasts (A) and 
cardiomyocytes (B) were identified by co-staining with anti-periostin I and anti-Tropoinin 
respectively. Results are expressed as percentage of apoptotic cells for each cell type ±SE. 
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